<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=12422"><dc:title>Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of &gt;= 1 by the USA Food and Drug Administration</dc:title><dc:creator>Mountzios,	Giannis	(Avtor)
	</dc:creator><dc:creator>Remon,	J.	(Avtor)
	</dc:creator><dc:creator>Novello,	Silvia	(Avtor)
	</dc:creator><dc:creator>Blais,	N.	(Avtor)
	</dc:creator><dc:creator>Califano,	R.	(Avtor)
	</dc:creator><dc:creator>Čufer,	Tanja	(Avtor)
	</dc:creator><dc:creator>Dingemans,	Anne-Marie C.	(Avtor)
	</dc:creator><dc:creator>Liu,	S. V.	(Avtor)
	</dc:creator><dc:creator>Peled,	N.	(Avtor)
	</dc:creator><dc:creator>Pennell,	N. A.	(Avtor)
	</dc:creator><dc:subject>non-small cell lung carcinoma</dc:subject><dc:subject>drug therapy</dc:subject><dc:subject>KEYNOTE-024 trial</dc:subject><dc:subject>pemrolizumab</dc:subject><dc:subject>treatment</dc:subject><dc:publisher>Elsevier</dc:publisher><dc:date>2019</dc:date><dc:date>2020-09-21 11:57:10</dc:date><dc:type>Neznano</dc:type><dc:identifier>12422</dc:identifier><dc:language>sl</dc:language><dc:rights>© 2019 THE AUTHORS</dc:rights></rdf:Description></rdf:RDF>